Skip to main content
. 2017 Aug 18;36(12):2655–2665. doi: 10.1007/s10067-017-3788-1

Fig. 1.

Fig. 1

Proportions of patients receiving subcutaneous (SC) or intravenous (IV) abatacept achieving Disease Activity Score 28 (DAS28; C-reactive protein) remission over 6 months by baseline body mass index in a the separate analyses and b the pooled analysis by route of abatacept administration. As-observed analysis in the intent-to-treat population (> 90% of patients reached the final observation at day 169). Error bars represent 95% confidence intervals